Agios Appoints Brian Goff as Chief Executive Officer Read more about Agios Appoints Brian Goff as Chief Executive Officer
Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress Read more about Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress
Agios Announces Evolution of Research Organization Read more about Agios Announces Evolution of Research Organization
Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress Read more about Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022 Read more about Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022
Agios at 2022 RBC Capital Markets Global Healthcare Conference Read more about Agios at 2022 RBC Capital Markets Global Healthcare Conference
Agios Reports Business Highlights and First Quarter 2022 Financial Results Read more about Agios Reports Business Highlights and First Quarter 2022 Financial Results
Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022 Read more about Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022
Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency Read more about Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency
Agios to Participate in March Investor Conferences Read more about Agios to Participate in March Investor Conferences